FDA reviews a proposed Keytruda biosimilar, Roche expands its obesity pipeline with an RNAi deal, and guselkumab shows promise for fistula remission in Crohn disease.
|Articles|March 13, 2012
FDA Issues Guidance Agenda for 2012
Author(s)Angie Drakulich
FDA has issued a list of planned draft and final guidance documents for release throughout 2012.
Advertisement
FDA has issued a list of planned draft and final guidance documents for release throughout 2012. There are about 50 such
In biopharmaceutics and biosimilarity:
- Food-Effect Bioavailability and Fed Bioequivalence Studies—Bioavailability and Bioequivalence Studies for Orally Administered Drug Products Submitted in New Drug Applications General Consideration
- Scientific Considerations in Demonstrating Biosimilarity To a Reference Product (draft already issued)
- Quality Considerations in Demonstrating Biosimilarity To a Reference Protein Product (draft already issued)
- Biosimilars: Questions and Answers Regarding Implementation of the Biologics Price Competition and Innovation Act of 2009 (draft already issued)
In combination products:
- Development of Drugs in Combination
In CGMPs and compliance:
- Control of Highly Potent Compounds
- Expiration Dating of Unit-Dose Repackaged Drugs: Compliance Policy Guide
- Importation of Active Pharmaceutical Ingredients (API) for Use in Human Drugs
In labeling, packaging, and supply chain:
- Naming, Labeling, and Packaging Practices to Reduce Medication Errors
- Securing the Drug Supply Chain—Standards for Tracking and Tracing Prescription Drug Packages
- Drug Names and Dosage Forms
- Organ-Specific Warnings: Internal Analgesic, Antipyretic and Antirheumatic Drug Products for Over-the-Counter Human Use-Labeling of Products That Contain Acetaminophen
- Pediatric Information: Incorporating into Human Prescription Drug and Biological Products Labeling
In regulatory filings (electronic):
- Providing Regulatory Submissions in Electronic Format – General Considerations
- Providing Regulatory Submissions in Electronic Format – Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications
- Providing Regulatory Submissions in Electronic Format – Study Data
- Providing Regulatory Submissions in Electronic Format – Standardized Study Data
Advertisement
Related to this article
Dr. Paz Vellanki discusses Bayesian methods, challenges in developing rare disease endpoints, and why sponsors should engage FDA early in clinical development.
As ArsenalBio, TScan, and others abandon ex vivo programs for in vivo engineering, early clinical data and platform differences point to both the promise and the unresolved safety, manufacturing, and regulatory questions of generating CAR-T cells inside the body.
Johnson & Johnson's guselkumab achieved up to 29% fistula remission in hard-to-treat Crohn disease subgroups, including prior biologic failures.
Rona's ALK7 RNAi candidate, licensed to Roche for up to $1.06 billion in milestones, aims to cut visceral fat while sparing lean mass.
FDA has accepted for review the biologics license application for FYB206, a proposed pembrolizumab biosimilar developed without a comparative phase 3 efficacy trial. A decision could come in the third quarter of 2027.
In an eight-week obese non-human primate study, lean mass made up 6% of the weight lost with iBio’s Activin E antibody IBIO-610 plus semaglutide, compared with 22% with semaglutide alone. iBio plans to begin first-in-human studies in the first half of 2027.
Clinical results reveal new opportunities and setbacks in rare disease and cancer care, shaping treatment strategies and future regulatory decisions.
Advertisement
Advertisement